These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 23647370

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.
    Usher-Smith JA, Ramsbottom T, Pearmain H, Kirby M.
    Int J Clin Pract; 2007 Jan; 61(1):15-23. PubMed ID: 17229176
    [Abstract] [Full Text] [Related]

  • 24. Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial).
    März W, Wollschläger H, Klein G, Neiss A, Wehling M.
    Am J Cardiol; 1999 Jul 01; 84(1):7-13. PubMed ID: 10404843
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG, Ballantyne CM, Hsueh WA, Rosen JB, Lin J, Shah AK, Tomassini JE, Lowe RS, Tershakovec AM.
    J Clin Lipidol; 2013 Jul 01; 7(4):292-303. PubMed ID: 23890516
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study.
    Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS.
    Curr Med Res Opin; 2008 Jul 01; 24(7):1987-2000. PubMed ID: 18554430
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets (TNT) Investigators.
    N Engl J Med; 2005 Apr 07; 352(14):1425-35. PubMed ID: 15755765
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.
    Simpson RJ, Signorovitch J, Birnbaum H, Ivanova J, Connolly C, Kidolezi Y, Kuznik A.
    Mayo Clin Proc; 2009 Dec 07; 84(12):1065-72. PubMed ID: 19955243
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Successful reintroduction of statin therapy after myositis: was there another cause?
    Rando LP, Cording SA, Newnham HH.
    Med J Aust; 2004 May 03; 180(9):472-3. PubMed ID: 15115429
    [No Abstract] [Full Text] [Related]

  • 40. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
    Foody JM, Brown WV, Zieve F, Adewale AJ, Flaim D, Lowe RS, Jones-Burton C, Tershakovec AM.
    Am J Cardiol; 2010 Nov 01; 106(9):1255-63. PubMed ID: 21029821
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.